Search
Inovio Pharmaceuticals Inc
INOAdd to Watchlist
1.220USD
+0.030+2.52%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
84.18MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.52%
5 Days
+10.91%
1 Month
-4.69%
6 Months
-29.89%
Year to Date
-29.89%
1 Year
-40.20%
Key Figures
1.200Open
1.270High
2.76MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
4.00%Turnover Ratio
1.190Prev. Close
1.180Low
2.46MTurnover
LossP/E Static
3.49P/B
0.00%Div Yield TTM
-123.95%ROA
2.97952wk High
2.96Volume Ratio
-107.25MNet Profit
69.00MShares
-1.5865EPS TTM
1.48Beta
-296.36%ROE
1.03052wk Low
7.56%Amplitude
100.00%Gross Margin
84.18MMarket Cap
1.02Reward/Risk
4.31%Risk Rate
TradingKey Stock Score of Inovio Pharmaceuticals Inc
Currency: USD Updated: 2026-07-01Key Insights
Inovio Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 156 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.43.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Inovio Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Inovio Pharmaceuticals Inc Highlights
StrengthsRisks
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.34K.
Undervalued
The company’s latest PE is -0.75, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 32.85M shares, increasing 8.46% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 98.83 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.09.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
3.433
Target Price
+206.55%
Upside Space
Inovio Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Inovio Pharmaceuticals Inc Info
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Ticker SymbolINO
CompanyInovio Pharmaceuticals Inc
CEOShea (Jacqueline Elizabeth)
Websitehttps://www.inovio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Inovio Pharmaceuticals Inc (INO)?
The current price of Inovio Pharmaceuticals Inc (INO) is 1.19.
What is the symbol of Inovio Pharmaceuticals Inc?
The ticker symbol of Inovio Pharmaceuticals Inc is INO.
What is the 52-week high of Inovio Pharmaceuticals Inc?
The 52-week high of Inovio Pharmaceuticals Inc is 2.98.
What is the 52-week low of Inovio Pharmaceuticals Inc?
The 52-week low of Inovio Pharmaceuticals Inc is 1.03.
What is the market capitalization of Inovio Pharmaceuticals Inc?
The market capitalization of Inovio Pharmaceuticals Inc is 97.91M.
Is Inovio Pharmaceuticals Inc (INO) currently rated as Buy, Hold, or Sell?
According to analysts, Inovio Pharmaceuticals Inc (INO) has an overall rating of Buy, with a price target of 3.43.
What is the Earnings Per Share (EPS TTM) of Inovio Pharmaceuticals Inc (INO)?
The Earnings Per Share (EPS TTM) of Inovio Pharmaceuticals Inc (INO) is -1.81.